GlobeNewswire: Obalon Therapeutics, Inc. Contains the last 10 of 104 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T11:39:32ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2021/05/12/2228182/0/en/Obalon-Announces-First-Quarter-2021-Financial-Results.html?f=22&fvtc=4&fvtv=29781Obalon Announces First Quarter 2021 Financial Results2021-05-12T12:40:00Z<![CDATA[SAN DIEGO, May 12, 2021 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the first quarter ended March 31, 2021. On January 19, 2020 the Company signed a definitive agreement for a merger with ReShape Lifesciences Inc.]]>https://www.globenewswire.com/news-release/2021/03/13/2192371/0/en/Obalon-Announces-Fourth-Quarter-and-Full-Year-2020-Financial-Results.html?f=22&fvtc=4&fvtv=29781Obalon Announces Fourth Quarter and Full Year 2020 Financial Results2021-03-13T00:12:24Z<![CDATA[SAN DIEGO, March 12, 2021 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the fourth quarter and full year ended December 31, 2020. On November 10, 2020, the Company signed a non-binding term sheet for merger with ReShape Lifesciences Inc. and, on January 20, 2021, announced that a definitive agreement had been signed on January 19, 2020 for a merger with ReShape Lifesciences Inc.]]>https://www.globenewswire.com/news-release/2020/11/06/2122223/0/en/Obalon-Announces-Third-Quarter-2020-Financial-Results.html?f=22&fvtc=4&fvtv=29781Obalon Announces Third Quarter 2020 Financial Results2020-11-06T21:45:00Z<![CDATA[SAN DIEGO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the third quarter ended September 30, 2020.]]>https://www.globenewswire.com/news-release/2020/08/13/2077790/0/en/Obalon-Announces-Consulting-Agreement-As-Part-of-Strategy-To-Seek-Coverage-and-Reimbursement-for-The-Obalon-Balloon-System.html?f=22&fvtc=4&fvtv=29781Obalon Announces Consulting Agreement As Part of Strategy To Seek Coverage and Reimbursement for The Obalon Balloon System2020-08-13T11:00:00Z<![CDATA[SAN DIEGO, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (Nasdaq: OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that it has executed a consulting agreement with Blue Ox Healthcare Partners, LLC, a private equity firm focused on commercial-ready companies bringing technology enabled innovation to healthcare, especially those involved in precision health, healthcare delivery, and affordability.]]>https://www.globenewswire.com/news-release/2020/07/30/2070152/0/en/Obalon-Announces-Second-Quarter-2020-Financial-Results.html?f=22&fvtc=4&fvtv=29781Obalon Announces Second Quarter 2020 Financial Results2020-07-30T10:38:04Z<![CDATA[SAN DIEGO, July 30, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the second quarter ended June 30, 2020.]]>https://www.globenewswire.com/news-release/2020/06/19/2050603/0/en/Obalon-Announces-First-Quarter-2020-Financial-Results-and-Business-Update.html?f=22&fvtc=4&fvtv=29781Obalon Announces First Quarter 2020 Financial Results and Business Update2020-06-19T10:15:00Z<![CDATA[SAN DIEGO, June 19, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (Nasdaq: OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the first quarter ended March 31, 2020 and provided a business update.]]>https://www.globenewswire.com/news-release/2020/05/11/2031090/0/en/Obalon-Announces-Further-Impacts-Related-To-Covid-19-Crisis-and-Current-Business-Environment.html?f=22&fvtc=4&fvtv=29781Obalon Announces Further Impacts Related To Covid-19 Crisis and Current Business Environment2020-05-11T12:30:00Z<![CDATA[SAN DIEGO, May 11, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (“Obalon” or the “Company”) (NASDAQ:OBLN), a vertically integrated weight loss solutions company commercializing the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces changes related to the impacts of the Covid-19 crisis and current business environment on its business, organization and strategic options.]]>https://www.globenewswire.com/news-release/2020/05/08/2030319/0/en/William-Plovanic-Resigns-as-President-and-Chief-Executive-Officer-and-Will-Continue-to-Serve-Solely-as-Director.html?f=22&fvtc=4&fvtv=29781William Plovanic Resigns as President and Chief Executive Officer and Will Continue to Serve Solely as Director2020-05-08T12:00:00Z<![CDATA[Obalon’s Executive Chairman, Andy Rasdal, will reassume CEO position Obalon’s Executive Chairman, Andy Rasdal, will reassume CEO position]]>https://www.globenewswire.com/news-release/2020/04/28/2023375/0/en/Obalon-Gas-Filled-Balloon-Not-Subject-of-Fourth-FDA-Letter-to-Health-Care-Providers-Related-To-Serious-Risks-Including-Death-With-Liquid-Filled-Intragastric-Balloons.html?f=22&fvtc=4&fvtv=29781Obalon Gas-Filled Balloon Not Subject of Fourth FDA Letter to Health Care Providers Related To Serious Risks, Including Death, With Liquid-Filled Intragastric Balloons2020-04-28T13:00:00Z<![CDATA[Obalon reported no device-related serious adverse events (0%) for first 141 patients completing therapy in post-approval study to FDA Obalon reported no device-related serious adverse events (0%) for first 141 patients completing therapy in post-approval study to FDA]]>https://www.globenewswire.com/news-release/2020/03/25/2006216/0/en/Obalon-Engages-Canaccord-Genuity-to-Explore-Financial-and-Strategic-Alternatives.html?f=22&fvtc=4&fvtv=29781Obalon Engages Canaccord Genuity to Explore Financial and Strategic Alternatives2020-03-25T12:30:00Z<![CDATA[SAN DIEGO, March 25, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated weight loss solutions company commercializing the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that its Board of Directors has decided to explore potential financial and strategic alternatives intended to enhance stockholder value. The Company has engaged Canaccord Genuity LLC as its financial advisor.]]>